Pancreatic Cancer Research

ResearcherNankai UniversityActive in the last 2 years

Chongbiao Huang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-9468-9168; OpenAlex author ID A5001077325. Sources: OpenAlex.

Their work

Papers
42 (first author 0, last author 4)
Trials
0
Grants
0
Labs led
1
Collaborators
77
Papers, trials and grants by year

2015: 3 papers · 2016: 2 papers · 2017: 3 papers · 2018: 1 paper · 2019: 2 papers · 2020: 1 paper · 2021: 3 papers · 2022: 7 papers · 2023: 6 papers · 2024: 5 papers · 2025: 5 papers · 2026: 4 papers

Papers 42

  1. Tumor-Derived Interleukin 35 Promotes Fibrosis in the Tumor Microenvironment of Pancreatic Cancer by Activating Pancreatic Stellate Cells. Last author DOI 10.1002/advs.202509074↗
  2. Retraction Note: BICC1 drives pancreatic cancer progression by inducing VEGF-independent angiogenesis. Co-author DOI 10.1038/s41392-025-02561-9↗
  3. Trogocytosis-orchestrated CLDN18.2-"dressed" CD8+ T cells drive pancreatic cancer progression via glucose metabolic reprogramming-induced cytotoxicity debilita… Co-author DOI 10.1136/gutjnl-2025-335790↗
  4. Senescent Cancer-Associated Fibroblasts Drive Early-Stage Lymph Node Metastasis in Pancreatic Cancer through Lactate-Mediated Metabolic-Epigenetic Rewiring. Co-author DOI 10.1158/2159-8290.cd-25-1627↗
  5. The nuclear condensates of ESE3/EHF induce cellular senescence without the associated inflammatory secretory phenotype in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.canlet.2024.217408↗
  6. A CD147-targeted small-molecule inhibitor potentiates gemcitabine efficacy by triggering ferroptosis in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.xcrm.2025.102292↗
  7. Nociceptor neurons promote PDAC progression and cancer pain by interaction with cancer-associated fibroblasts and suppression of natural killer cells. Co-author DOI 10.1038/s41422-025-01098-4↗
  8. Targeting TNK2/ACK1 reverses the immunosuppressive tumor microenvironment and synergizes with immunochemotherapy in pancreatic cancer. Co-author DOI 10.1038/s41467-025-67197-3↗
  9. CLT-003 exerts anti-tumor activity in pancreatic cancer by blocking the PI3K/AKT/HIF-1α pathway. Co-author DOI 10.20892/j.issn.2095-3941.2025.0058↗
  10. Tumor-derived interleukin 35 mediates the dissemination of gemcitabine resistance in pancreatic adenocarcinoma. Last author DOI 10.1038/s41388-024-02938-0↗
  11. Correction: BICC1 drives pancreatic cancer progression by inducing VEGF-independent angiogenesis. Co-author DOI 10.1038/s41392-023-01721-z↗
  12. Targeting ESE3/EHF With Nifurtimox Inhibits CXCR2+ Neutrophil Infiltration and Overcomes Pancreatic Cancer Resistance to Chemotherapy and Immunotherapy. Co-author DOI 10.1053/j.gastro.2024.02.046↗
  13. BICC1 drives pancreatic cancer stemness and chemoresistance by facilitating tryptophan metabolism. Co-author DOI 10.1126/sciadv.adj8650↗
  14. CD64+ fibroblast-targeted vilanterol and a STING agonist augment CLDN18.2 BiTEs efficacy against pancreatic cancer by reducing desmoplasia and enriching stem-l… Co-author DOI 10.1136/gutjnl-2024-332371↗
  15. CD73, a Promising Therapeutic Target of Diclofenac, Promotes Metastasis of Pancreatic Cancer through a Nucleotidase Independent Mechanism. Co-author DOI 10.1002/advs.202206335↗
  16. BICC1 drives pancreatic cancer progression by inducing VEGF-independent angiogenesis. Co-author DOI 10.1038/s41392-023-01478-5↗
  17. Selective extended dissection for pancreaticoduodenectomy is associated with better survival in pancreatic cancer patients: retrospective cohort study. Co-author DOI 10.1097/js9.0000000000000437↗
  18. SDCBP promotes pancreatic cancer progression by preventing YAP1 from β-TrCP-mediated proteasomal degradation. Co-author DOI 10.1136/gutjnl-2022-327492↗
  19. Irbesartan overcomes gemcitabine resistance in pancreatic cancer by suppressing stemness and iron metabolism via inhibition of the Hippo/YAP1/c-Jun axis. Co-author DOI 10.1186/s13046-023-02671-8↗
  20. Nuclear PLD1 combined with NPM1 induces gemcitabine resistance through tumorigenic IL7R in pancreatic adenocarcinoma. Co-author DOI 10.20892/j.issn.2095-3941.2023.0039↗
  21. Genome-wide CRISPR screen identifies MTA3 as an inducer of gemcitabine resistance in pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.canlet.2022.215864↗
  22. ESE3-positive PSCs drive pancreatic cancer fibrosis, chemoresistance and poor prognosis via tumour-stromal IL-1β/NF-κB/ESE3 signalling axis. Co-author DOI 10.1038/s41416-022-01927-y↗
  23. BZW1 Facilitates Glycolysis and Promotes Tumor Growth in Pancreatic Ductal Adenocarcinoma Through Potentiating eIF2α Phosphorylation. Co-author DOI 10.1053/j.gastro.2021.12.249↗
  24. ESE3/EHF, a promising target of rosiglitazone, suppresses pancreatic cancer stemness by downregulating CXCR4. Co-author DOI 10.1136/gutjnl-2020-321952↗
  25. Mitochondrial Calcium Uniporter Drives Metastasis and Confers a Targetable Cystine Dependency in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-21-3230↗
  26. MIF promotes cell invasion by the LRP1-uPAR interaction in pancreatic cancer cells. Last author DOI 10.3389/fonc.2022.1028070↗
  27. Perioperative Serum Scoring Systems Predict Early Recurrence and Poor Prognosis of Resectable Pancreatic Cancer. Co-author DOI 10.3389/fonc.2022.841819↗
  28. PERK-eIF2α-ERK1/2 axis drives mesenchymal-endothelial transition of cancer-associated fibroblasts in pancreatic cancer. Co-author DOI 10.1016/j.canlet.2021.05.021↗
  29. CD73 induces gemcitabine resistance in pancreatic ductal adenocarcinoma: A promising target with non-canonical mechanisms. Co-author DOI 10.1016/j.canlet.2021.07.024↗
  30. Hypoxic microenvironment induced spatial transcriptome changes in pancreatic cancer. Co-author DOI 10.20892/j.issn.2095-3941.2021.0158↗
  31. IL-37/ STAT3/ HIF-1α negative feedback signaling drives gemcitabine resistance in pancreatic cancer. Co-author DOI 10.7150/thno.42416↗
  32. Tumoral EHF predicts the efficacy of anti-PD1 therapy in pancreatic ductal adenocarcinoma. Co-author DOI 10.1084/jem.20180749↗
  33. LIMS1 Promotes Pancreatic Cancer Cell Survival under Oxygen-Glucose Deprivation Conditions by Enhancing HIF1A Protein Translation. Co-author DOI 10.1158/1078-0432.ccr-18-3533↗
  34. Interleukin 35 Expression Correlates With Microvessel Density in Pancreatic Ductal Adenocarcinoma, Recruits Monocytes, and Promotes Growth and Angiogenesis of … Co-author DOI 10.1053/j.gastro.2017.09.039↗
  35. Tumour-derived Interleukin 35 promotes pancreatic ductal adenocarcinoma cell extravasation and metastasis by inducing ICAM1 expression. Co-author DOI 10.1038/ncomms14035↗
  36. Cancer-FOXP3 directly activated CCL5 to recruit FOXP3+Treg cells in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/onc.2016.458↗
  37. ESE3 Inhibits Pancreatic Cancer Metastasis by Upregulating E-Cadherin. Co-author DOI 10.1158/0008-5472.can-16-2170↗
  38. Arsenic trioxide plus PX-478 achieves effective treatment in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.canlet.2016.05.016↗
  39. Hypoxia Inducible Factor 1 (HIF-1) Recruits Macrophage to Activate Pancreatic Stellate Cells in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/ijms17060799↗
  40. Wnt2 protein plays a role in the progression of pancreatic cancer promoted by pancreatic stellate cells. Co-author DOI 10.1007/s12032-015-0513-2↗
  41. LASP1 is a HIF1α target gene critical for metastasis of pancreatic cancer. Co-author DOI 10.1158/0008-5472.can-14-2040↗
  42. Inhibition of HIF-1α by PX-478 enhances the anti-tumor effect of gemcitabine by inducing immunogenic cell death in pancreatic ductal adenocarcinoma. Co-author DOI 10.18632/oncotarget.2948↗

Closest collaborators

The 25 strongest of 77 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jihui Hao · 38 shared papers, 2015–2026 · strength 5.10
  2. Tiansuo Zhao · 32 shared papers, 2015–2026 · strength 4.21
  3. Xiuchao Wang · 31 shared papers, 2015–2026 · strength 4.03
  4. Song Gao · 24 shared papers, 2015–2026 · strength 3.30
  5. Shengyu Yang · 23 shared papers, 2016–2026 · strength 2.82
  6. Jing Liu · 16 shared papers, 2019–2026 · strength 2.31
  7. Tianxing Zhou · 12 shared papers, 2019–2026 · strength 1.95
  8. Yongjie Xie · 11 shared papers, 2022–2026 · strength 1.87
  9. Huizhi Sun · 10 shared papers, 2021–2026 · strength 1.67
  10. Yukuan Feng · 7 shared papers, 2024–2026 · strength 1.40
  11. Chao Xu · 6 shared papers, 2023–2026 · strength 1.16
  12. Zengxun Li · 9 shared papers, 2016–2026 · strength 1.14
  13. Wenna Jiang · 8 shared papers, 2016–2024 · strength 0.90
  14. Chao Yang · 4 shared papers, 2025–2026 · strength 0.79
  15. Jun Yu · 4 shared papers, 2024–2026 · strength 0.73
  16. Hui Li · 3 shared papers, 2024–2026 · strength 0.66
  17. Danqi Fu · 5 shared papers, 2019–2024 · strength 0.65
  18. Weishuai Liu · 4 shared papers, 2021–2025 · strength 0.58
  19. Peng Xie · 3 shared papers, 2023–2026 · strength 0.56
  20. Liangliang Wu · 4 shared papers, 2021–2025 · strength 0.55
  21. Bo Ni · 3 shared papers, 2024–2025 · strength 0.53
  22. Yiping Zou · 3 shared papers, 2024–2025 · strength 0.53
  23. Chuntao Gao · 4 shared papers, 2021–2023 · strength 0.52
  24. Shengnan Li · 3 shared papers, 2022–2025 · strength 0.47
  25. Ying Ma · 3 shared papers, 2021–2025 · strength 0.44

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.